We remain in the summer doldrums but more than that we are stuck in the macro issues. Between a potential recession to the China trade war, it is virtually impossible to get through a week without something whipping the sector and market. Today we might actually be getting to a point where China starts to […]
August 2 Biotech Update
So it looked like yesterday was the day that all the good news was finally going to push the sector higher and we get the China tariffs macro news. Clearly the sector cannot catch a break and all of this good news now runs the risk of being buried in macro issues. There is still […]
February 19 Biotech Update
The sector might be peaking its head above the top end of the range. The ideal set up for breakout are moves above the range and then successfully testing the upper end of the previous range where it would now act as support instead of resistance. At this point, we look to be moving out […]
January 24 Biotech Update
Another day and another chance to grind away at these levels. Yesterday was pretty weak and it will be interesting to see how the sector reacts. If we have an inside day, then perhaps the near term trend remains the grind but if we break below yesterday’s low then it is another sign that the […]
October 18 Biotech Update
We finally have some M&A in the sector but I am not convinced it will have a very broad effect. While it is not a small deal, the $2B or so price tag is not game changing for anyone. In addition, the top holders were overwhelmingly biotech specialists and not generalists. Clearly it will be […]
October 5 Biotech Update
Yesterday was brutal to say the least. There really was nothing to like about it. The XBI seems to have broken below its range and the IBB is rushing to the bottom end of its range. I have been talking about the XBI as the early warning index for the IBB and unless it can […]
July 31 Biotech Update
I am still trying to catch up on all the earnings and happenings last week but I wanted to talk about two broad observations. In some ways, I benefited from not being able to watch the price action last week and only really looked at the news. In general, the price action does not reflect […]
Dave Trading July 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
Dave-Trading – June 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
June 20 Biotech Update
You would think replacing a computer would be an easy job, it apparently requires different layers of people and so not everyone was on campus yesterday. So at some point in the future I have to look forward to the computer replacement process to eat half of my day. In any case, at least the […]
June 6 Biotech Update
The sector did a little better yesterday but given the strength of the market, it is not a great performance. That being said another couple days in the green and perhaps this year will be different and we will not see the post-ASCO selloff. Obviously it is early but something to keep an eye on […]
May 31 Biotech Update
Some interesting news as we head into ASCO. While the trading action is a little better for the sector it is not exactly tearing it up. Of course, the lack of a real ASCO run up generally does not correlate with a lower than average chance of an ASCO hangover. It is possible that it […]
Dave-Trading – June 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
Dave Trading – May 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
April 2 Biotech Update
Thursday was not a bad follow through for the sector. I am still not convinced that we are out of the forest quite yet but we are at least further away from the abyss that was staring at the sector earlier last week. This week looks to be quiet to start as there is not […]
Dave Trading – April 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
February 23 Biotech Update
The market is looking a little shaky. It is not as if the selling is sending it down but every single spike in the past couple days has been sold. I see that as a lot of overhead supply of stock for sale, which is not great. On the plus side, the support below these […]
February 2 Biotech Update
It looks like the correction continues. Fundamental news does not seem to be matter a lot this week, which seems like typical price action during a correction. This does not seem sector specific and I doubt that it becomes anything more than a correction in a larger bull market but that does not mean it […]
January 11 Biotech Update
While we still have two trading days left this week, it looks like we will end up with a decent performance for the sector. Given the lack of news at JPM, this appears to be a win (assuming it continues) and seems to support the argument that the Monday selling was fast money getting out […]
November 20 Biotech Update
The news is winding down as we get closer to the holidays but there is some news today. For the most part, I do not expect a lot of news but there could be an M&A push to end the year if bankers need more deals for their bonuses. That being said I think we […]
